NOSCIRA S.A.
The legal basis for the treatment of the data is the consent granted by the User when providing the data. The data will be kept while the relationship is maintained and its deletion is not requested and in any case in compliance with statutory limitation periods that may be applicable.
NOSCIRA S.A.
Social Links:
Industry:
Biopharma Pharmaceutical
Address:
Madrid, Madrid, Spain
Country:
Spain
Website Url:
http://www.noscira.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright Adobe ColdFusion
Official Site Inspections
http://www.noscira.com
- Host name: 172.67.214.194
- IP address: 172.67.214.194
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Noscira S.A."
Noscira S.A. - Crunchbase Company Profile & Funding
Noscira S.A. is a Spanish biopharmaceutical company. Madrid, Madrid, Spain. 51-100. Private. noscira.com/ 537,245. Highlights. Similar Companies 4. Recent News & Activity. There is no recent news or activity for this profile. Details. โฆSee details»
Organization | Noscira SA
Noscira SA Report issue. For profit Phase 2. Founded: Madrid Spain (2000 ... Organization Overview. First Clinical Trial. 2008 NCT00948259. First Marketed Drug. None First NDA โฆSee details»
Noscira - Products, Competitors, Financials, Employees, โฆ
Developer of drugs for the treatment and prevention of the nervous system disorders, particularly Alzheimer's disease. Use the CB Insights Platform to explore Noscira's full profile.See details»
Orphanet: Noscira S.A.
Noscira S.A. Avenida de la Industria, 52. 28760 TRES CANTOS . SPAIN. Phone 1: 34 (0)91 806 11 30 Contact email: [email protected]. Institution's website EUGT Number: 216775 โฆSee details»
Noscira S.A. - BioCentury Company Profiles - BCIQ
Dec 11, 2018ย ยท Company Profiles. Target Profiles. Product Profiles. Explore BCIQ profiles by entering a company name. REQUEST A FREE TRIAL. Overview. Pipeline. Deals. Financings. โฆSee details»
Noscira S.A. - Life-Sciences-Europe.com
Sep 1, 2008ย ยท BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl โ the European Association of Bioindustries; BioIndustry โฆSee details»
Noscira SA - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024ย ยท Explore Noscira SA with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, Drug:Tideglusib, NP-0361, NP-21, NP-0336, NP-901.See details»
Noscira S.A. - Crunchbase
Noscira S.A. is a Spanish biopharmaceutical companySee details»
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R ...
MADRID, July 15 /PRNewswire/ -- Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the โฆSee details»
Noscira SA - Drug pipelines, Patents, Clinical trials - Synapse
Explore Noscira SA with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, and 10 literature, Drug:NP-0361, Tideglusib, NP-103, NP-901, NP-21.See details»
Noscira Presents Results of Phase IIa Clinical Trial with ... - BioSpace
MADRID, July 15 /PRNewswire/ -- Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the โฆSee details»
Noscira S.A. - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 17, 2024ย ยท Noscira S.A. uses the technology HTML5, according to G2 Stack. Noscira S.A. is actively using 4 technologies for its website, according to BuiltWith. These include IPv6, โฆSee details»
FDA Grants Fast Track Status to Noscira's Tideglusib ... - BioSpace
Sep 10, 2010ย ยท MADRID, Sept. 9 /PRNewswire/ -- Noscira, a Grupo Zeltia (ZEL.MC) subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has โฆSee details»
NOSCIRA SA innovation strategy - GoodIP
Get understandable and actionable insights about the innovation strategy of NOSCIRA SA. Find out in which industries it is active in and who the biggest competitors are.See details»
Tideglusib - ALZFORUM
Jun 3, 2019ย ยท Tideglusib is an orally available, small-molecule drug of the thiadiazolidinone class. It acts as an inhibitor of glycogen synthase kinase 3 (GSK3-ฮฒ), a widely studied tau kinase.See details»
Design, Synthesis, and Biological Evaluation of ... - ACS Publications
The third-generation GSK3ฮฒ non-competitive ATP-binding site inhibitors include GSK3ฮฒ inhibitor 2, TDZD-8 and Tideglusib, and so forth. Tideglusib is the only third-generation GSK3ฮฒ inhibitor โฆSee details»
TIDEGLUSIB - New Drug Approvals
Jan 10, 2014ย ยท Tideglusib (NP-12, NP031112) is a potent, selective and irreversible [1] small molecule non- ATP -competitive GSK3 inhibitor that has been investigated as a potential โฆSee details»
The regenerative potential of Tideglusib and CHIR99021 small โฆ
Dec 28, 2023ย ยท Tideglusib (Noscira SA, Madrid, Spain) is a non-ATP competitive GSK-3 inhibitor small molecule. It is known for its neuroprotective effects and is currently being used in the โฆSee details»
Research programme: spinal cord injury cell therapy - Noscira
Noscira (a subsidiary of the Zeltia Group) was undertaking a research programme to develop a cell therapy product, OEG, for the treatment and neuronal.See details»
A phase 2 trial of the GSKโ3 inhibitor tideglusib in progressive ...
Feb 14, 2014ย ยท The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK โฆSee details»